Search

Your search keyword '"Kaufman, Bella"' showing total 494 results
Start Over Author "Kaufman, Bella"
494 results on '"Kaufman, Bella"'

2. Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer

Author

Tutt, Andrew NJ, Garber, Judy E, Kaufman, Bella, Viale, Giuseppe, Fumagalli, Debora, Rastogi, Priya, Gelber, Richard D, de Azambuja, Evandro, Fielding, Anitra, Balmaña, Judith, Domchek, Susan M, Gelmon, Karen A, Hollingsworth, Simon J, Korde, Larissa A, Linderholm, Barbro, Bandos, Hanna, Senkus, Elżbieta, Suga, Jennifer M, Shao, Zhimin, Pippas, Andrew W, Nowecki, Zbigniew, Huzarski, Tomasz, Ganz, Patricia A, Lucas, Peter C, Baker, Nigel, Loibl, Sibylle, McConnell, Robin, Piccart, Martine, Schmutzler, Rita, Steger, Guenther G, Costantino, Joseph P, Arahmani, Amal, Wolmark, Norman, McFadden, Eleanor, Karantza, Vassiliki, Lakhani, Sunil R, Yothers, Greg, Campbell, Christine, and Geyer, Charles E

Subjects
Digestive Diseases, Breast Cancer, Cancer, Clinical Research, Clinical Trials and Supportive Activities, 6.1 Pharmaceuticals, Evaluation of treatments and therapeutic interventions, Good Health and Well Being, Adult, Antineoplastic Agents, Breast Neoplasms, Chemotherapy, Adjuvant, Disease-Free Survival, Double-Blind Method, Female, Genes, BRCA1, Genes, BRCA2, Germ-Line Mutation, Humans, Mastectomy, Middle Aged, Phthalazines, Piperazines, Poly(ADP-ribose) Polymerase Inhibitors, Receptor, ErbB-2, OlympiA Clinical Trial Steering Committee and Investigators, Receptor, erbB-2, Medical and Health Sciences, General & Internal Medicine
Abstract

BackgroundPoly(adenosine diphosphate-ribose) polymerase inhibitors target cancers with defects in homologous recombination repair by synthetic lethality. New therapies are needed to reduce recurrence in patients with BRCA1 or BRCA2 germline mutation-associated early breast cancer.MethodsWe conducted a phase 3, double-blind, randomized trial involving patients with human epidermal growth factor receptor 2 (HER2)-negative early breast cancer with BRCA1 or BRCA2 germline pathogenic or likely pathogenic variants and high-risk clinicopathological factors who had received local treatment and neoadjuvant or adjuvant chemotherapy. Patients were randomly assigned (in a 1:1 ratio) to 1 year of oral olaparib or placebo. The primary end point was invasive disease-free survival.ResultsA total of 1836 patients underwent randomization. At a prespecified event-driven interim analysis with a median follow-up of 2.5 years, the 3-year invasive disease-free survival was 85.9% in the olaparib group and 77.1% in the placebo group (difference, 8.8 percentage points; 95% confidence interval [CI], 4.5 to 13.0; hazard ratio for invasive disease or death, 0.58; 99.5% CI, 0.41 to 0.82; P

Published
2021

7. Inheritance of deleterious mutations at both BRCA1 and BRCA2 in an international sample of 32,295 women.

Author

Rebbeck, Timothy R, Friebel, Tara M, Mitra, Nandita, Wan, Fei, Chen, Stephanie, Andrulis, Irene L, Apostolou, Paraskevi, Arnold, Norbert, Arun, Banu K, Barrowdale, Daniel, Benitez, Javier, Berger, Raanan, Berthet, Pascaline, Borg, Ake, Buys, Saundra S, Caldes, Trinidad, Carter, Jonathan, Chiquette, Jocelyne, Claes, Kathleen BM, Couch, Fergus J, Cybulski, Cezary, Daly, Mary B, de la Hoya, Miguel, Diez, Orland, Domchek, Susan M, Nathanson, Katherine L, Durda, Katarzyna, Ellis, Steve, EMBRACE, Evans, D Gareth, Foretova, Lenka, Friedman, Eitan, Frost, Debra, Ganz, Patricia A, Garber, Judy, Glendon, Gord, Godwin, Andrew K, Greene, Mark H, Gronwald, Jacek, Hahnen, Eric, Hallberg, Emily, Hamann, Ute, Hansen, Thomas VO, HEBON, Imyanitov, Evgeny N, Isaacs, Claudine, Jakubowska, Anna, Janavicius, Ramunas, Jaworska-Bieniek, Katarzyna, John, Esther M, Karlan, Beth Y, Kaufman, Bella, Investigators, KConFab, Kwong, Ava, Laitman, Yael, Lasset, Christine, Lazaro, Conxi, Lester, Jenny, Loman, Niklas, Lubinski, Jan, Manoukian, Siranoush, Mitchell, Gillian, Montagna, Marco, Neuhausen, Susan L, Nevanlinna, Heli, Niederacher, Dieter, Nussbaum, Robert L, Offit, Kenneth, Olah, Edith, Olopade, Olufunmilayo I, Park, Sue Kyung, Piedmonte, Marion, Radice, Paolo, Rappaport-Fuerhauser, Christine, Rookus, Matti A, Seynaeve, Caroline, Simard, Jacques, Singer, Christian F, Soucy, Penny, Southey, Melissa, Stoppa-Lyonnet, Dominique, Sukiennicki, Grzegorz, Szabo, Csilla I, Tancredi, Mariella, Teixeira, Manuel R, Teo, Soo-Hwang, Terry, Mary Beth, Thomassen, Mads, Tihomirova, Laima, Tischkowitz, Marc, Toland, Amanda Ewart, Toloczko-Grabarek, Aleksandra, Tung, Nadine, van Rensburg, Elizabeth J, Villano, Danylo, Wang-Gohrke, Shan, Wappenschmidt, Barbara, Weitzel, Jeffrey N, Zidan, Jamal, and Zorn, Kristin K

Subjects
EMBRACE, HEBON, Humans, Breast Neoplasms, Population Surveillance, Heterozygote, Phenotype, Loss of Heterozygosity, Germ-Line Mutation, Alleles, Genes, BRCA1, Genes, BRCA2, Exons, Female, Promoter Regions, Genetic, BRCA1, BRCA2, Hereditary breast and ovarian cancer, Transheterozygosity, Genes, Promoter Regions, Genetic, Clinical Research, Breast Cancer, Cancer, 2.1 Biological and endogenous factors, Oncology & Carcinogenesis, Oncology and Carcinogenesis
Abstract

BackgroundMost BRCA1 or BRCA2 mutation carriers have inherited a single (heterozygous) mutation. Transheterozygotes (TH) who have inherited deleterious mutations in both BRCA1 and BRCA2 are rare, and the consequences of transheterozygosity are poorly understood.MethodsFrom 32,295 female BRCA1/2 mutation carriers, we identified 93 TH (0.3 %). "Cases" were defined as TH, and "controls" were single mutations at BRCA1 (SH1) or BRCA2 (SH2). Matched SH1 "controls" carried a BRCA1 mutation found in the TH "case". Matched SH2 "controls" carried a BRCA2 mutation found in the TH "case". After matching the TH carriers with SH1 or SH2, 91 TH were matched to 9316 SH1, and 89 TH were matched to 3370 SH2.ResultsThe majority of TH (45.2 %) involved the three common Jewish mutations. TH were more likely than SH1 and SH2 women to have been ever diagnosed with breast cancer (BC; p = 0.002). TH were more likely to be diagnosed with ovarian cancer (OC) than SH2 (p = 0.017), but not SH1. Age at BC diagnosis was the same in TH vs. SH1 (p = 0.231), but was on average 4.5 years younger in TH than in SH2 (p

Published
2016

8. Veliparib with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer (BROCADE3): a randomised, double-blind, placebo-controlled, phase 3 trial

Author

Diéras, Véronique, Han, Hyo S, Kaufman, Bella, Wildiers, Hans, Friedlander, Michael, Ayoub, Jean-Pierre, Puhalla, Shannon L, Bondarenko, Igor, Campone, Mario, Jakobsen, Erik H, Jalving, Mathilde, Oprean, Cristina, Palácová, Marketa, Park, Yeon Hee, Shparyk, Yaroslav, Yañez, Eduardo, Khandelwal, Nikhil, Kundu, Madan G, Dudley, Matthew, Ratajczak, Christine K, Maag, David, and Arun, Banu K

Published
2020
Full Text
View/download PDF

9. Olaparib and durvalumab in patients with germline BRCA-mutated metastatic breast cancer (MEDIOLA): an open-label, multicentre, phase 1/2, basket study

Author

Domchek, Susan M, Postel-Vinay, Sophie, Im, Seock-Ah, Park, Yeon Hee, Delord, Jean-Pierre, Italiano, Antoine, Alexandre, Jerome, You, Benoit, Bastian, Sara, Krebs, Matthew G, Wang, Ding, Waqar, Saiama N, Lanasa, Mark, Rhee, Joon, Gao, Haiyan, Rocher-Ros, Vidalba, Jones, Emma V, Gulati, Sakshi, Coenen-Stass, Anna, Kozarewa, Iwanka, Lai, Zhongwu, Angell, Helen K, Opincar, Laura, Herbolsheimer, Pia, and Kaufman, Bella

Published
2020
Full Text
View/download PDF

13. Diagnostic yield of multigene panel testing in an Israeli cohort: enrichment of low-penetrance variants

Author

Bernstein-Molho, Rinat, Friedman, Eitan, Kedar, Inbal, Laitman, Yael, Allweis, Tanir M., Gal-Yam, Einav Nili, Feldman, Hagit Baris, Grinshpun, Albert, Halpern, Naama, Hartmajer, Shulamit, Kadouri, Luna, Katz, Lior H., Kaufman, Bella, Laish, Ido, Levanon, Keren, Philipsborn, Shira Litz, Ludman, Mark, Moran, Gal, Peretz, Tamar, Reinstein, Eyal, Levi, Gili Reznick, Safra, Tamar, Shkedi, Shiri, Vinkler, Chana, Levy, Zohar, and Goldberg, Yael

Published
2020
Full Text
View/download PDF

14. Supplementary Data Tables from Niraparib for Advanced Breast Cancer with Germline BRCA1 and BRCA2 Mutations: the EORTC 1307-BCG/BIG5–13/TESARO PR-30–50–10-C BRAVO Study

Author

Turner, Nicholas C., primary, Balmaña, Judith, primary, Poncet, Coralie, primary, Goulioti, Theodora, primary, Tryfonidis, Konstantinos, primary, Honkoop, Aafke H., primary, Zoppoli, Gabriele, primary, Razis, Evangelia, primary, Johannsson, Oskar T., primary, Colleoni, Marco, primary, Tutt, Andrew N., primary, Audeh, William, primary, Ignatiadis, Michail, primary, Mailliez, Audrey, primary, Trédan, Olivier, primary, Musolino, Antonino, primary, Vuylsteke, Peter, primary, Juan-Fita, Maria Jose, primary, Macpherson, Iain R.J., primary, Kaufman, Bella, primary, Manso, Luis, primary, Goldstein, Lori J., primary, Ellard, Susan L., primary, Láng, István, primary, Jen, Kai Yu, primary, Adam, Virginie, primary, Litière, Saskia, primary, Erban, John, primary, and Cameron, David A., primary

Published
2023
Full Text
View/download PDF

15. Supplementary Data Investigator Lists from Niraparib for Advanced Breast Cancer with Germline BRCA1 and BRCA2 Mutations: the EORTC 1307-BCG/BIG5–13/TESARO PR-30–50–10-C BRAVO Study

Author

Turner, Nicholas C., primary, Balmaña, Judith, primary, Poncet, Coralie, primary, Goulioti, Theodora, primary, Tryfonidis, Konstantinos, primary, Honkoop, Aafke H., primary, Zoppoli, Gabriele, primary, Razis, Evangelia, primary, Johannsson, Oskar T., primary, Colleoni, Marco, primary, Tutt, Andrew N., primary, Audeh, William, primary, Ignatiadis, Michail, primary, Mailliez, Audrey, primary, Trédan, Olivier, primary, Musolino, Antonino, primary, Vuylsteke, Peter, primary, Juan-Fita, Maria Jose, primary, Macpherson, Iain R.J., primary, Kaufman, Bella, primary, Manso, Luis, primary, Goldstein, Lori J., primary, Ellard, Susan L., primary, Láng, István, primary, Jen, Kai Yu, primary, Adam, Virginie, primary, Litière, Saskia, primary, Erban, John, primary, and Cameron, David A., primary

Published
2023
Full Text
View/download PDF

16. Supp Figure S1 from Niraparib for Advanced Breast Cancer with Germline BRCA1 and BRCA2 Mutations: the EORTC 1307-BCG/BIG5–13/TESARO PR-30–50–10-C BRAVO Study

Author

Turner, Nicholas C., primary, Balmaña, Judith, primary, Poncet, Coralie, primary, Goulioti, Theodora, primary, Tryfonidis, Konstantinos, primary, Honkoop, Aafke H., primary, Zoppoli, Gabriele, primary, Razis, Evangelia, primary, Johannsson, Oskar T., primary, Colleoni, Marco, primary, Tutt, Andrew N., primary, Audeh, William, primary, Ignatiadis, Michail, primary, Mailliez, Audrey, primary, Trédan, Olivier, primary, Musolino, Antonino, primary, Vuylsteke, Peter, primary, Juan-Fita, Maria Jose, primary, Macpherson, Iain R.J., primary, Kaufman, Bella, primary, Manso, Luis, primary, Goldstein, Lori J., primary, Ellard, Susan L., primary, Láng, István, primary, Jen, Kai Yu, primary, Adam, Virginie, primary, Litière, Saskia, primary, Erban, John, primary, and Cameron, David A., primary

Published
2023
Full Text
View/download PDF

17. Data from Niraparib for Advanced Breast Cancer with Germline BRCA1 and BRCA2 Mutations: the EORTC 1307-BCG/BIG5–13/TESARO PR-30–50–10-C BRAVO Study

Author

Turner, Nicholas C., primary, Balmaña, Judith, primary, Poncet, Coralie, primary, Goulioti, Theodora, primary, Tryfonidis, Konstantinos, primary, Honkoop, Aafke H., primary, Zoppoli, Gabriele, primary, Razis, Evangelia, primary, Johannsson, Oskar T., primary, Colleoni, Marco, primary, Tutt, Andrew N., primary, Audeh, William, primary, Ignatiadis, Michail, primary, Mailliez, Audrey, primary, Trédan, Olivier, primary, Musolino, Antonino, primary, Vuylsteke, Peter, primary, Juan-Fita, Maria Jose, primary, Macpherson, Iain R.J., primary, Kaufman, Bella, primary, Manso, Luis, primary, Goldstein, Lori J., primary, Ellard, Susan L., primary, Láng, István, primary, Jen, Kai Yu, primary, Adam, Virginie, primary, Litière, Saskia, primary, Erban, John, primary, and Cameron, David A., primary

Published
2023
Full Text
View/download PDF

18. Breast Cancer (Diagnosed) During Pregnancy: Adapting Recent Advances in Breast Cancer Care for Pregnant Patients

Author

Loibl, Sibylle, Schmidt, André, Gentilini, Oreste D., Kaufman, Bella, Kuhl, Christine, Denkert, Carsten, von Minckwitz, Gunter, Parokonnaya, Anastasia, Stensheim, Hanne, Thomssen, Christoph, van Calsteren, Kristel, Poortmans, Philip, Berveiller, Paul, Markert, Udo, Amant, Frederic, Veronesi, Umberto, editor, Goldhirsch, Aron, editor, Veronesi, Paolo, editor, Gentilini, Oreste Davide, editor, and Leonardi, Maria Cristina, editor

Published
2017
Full Text
View/download PDF

22. Interplay between BRCA1 and RHAMM regulates epithelial apicobasal polarization and may influence risk of breast cancer.

Author

Maxwell, Christopher A, Benítez, Javier, Gómez-Baldó, Laia, Osorio, Ana, Bonifaci, Núria, Fernández-Ramires, Ricardo, Costes, Sylvain V, Guinó, Elisabet, Chen, Helen, Evans, Gareth JR, Mohan, Pooja, Català, Isabel, Petit, Anna, Aguilar, Helena, Villanueva, Alberto, Aytes, Alvaro, Serra-Musach, Jordi, Rennert, Gad, Lejbkowicz, Flavio, Peterlongo, Paolo, Manoukian, Siranoush, Peissel, Bernard, Ripamonti, Carla B, Bonanni, Bernardo, Viel, Alessandra, Allavena, Anna, Bernard, Loris, Radice, Paolo, Friedman, Eitan, Kaufman, Bella, Laitman, Yael, Dubrovsky, Maya, Milgrom, Roni, Jakubowska, Anna, Cybulski, Cezary, Gorski, Bohdan, Jaworska, Katarzyna, Durda, Katarzyna, Sukiennicki, Grzegorz, Lubiński, Jan, Shugart, Yin Yao, Domchek, Susan M, Letrero, Richard, Weber, Barbara L, Hogervorst, Frans BL, Rookus, Matti A, Collee, J Margriet, Devilee, Peter, Ligtenberg, Marjolijn J, Luijt, Rob B van der, Aalfs, Cora M, Waisfisz, Quinten, Wijnen, Juul, Roozendaal, Cornelis EP van, HEBON, EMBRACE, Easton, Douglas F, Peock, Susan, Cook, Margaret, Oliver, Clare, Frost, Debra, Harrington, Patricia, Evans, D Gareth, Lalloo, Fiona, Eeles, Rosalind, Izatt, Louise, Chu, Carol, Eccles, Diana, Douglas, Fiona, Brewer, Carole, Nevanlinna, Heli, Heikkinen, Tuomas, Couch, Fergus J, Lindor, Noralane M, Wang, Xianshu, Godwin, Andrew K, Caligo, Maria A, Lombardi, Grazia, Loman, Niklas, Karlsson, Per, Ehrencrona, Hans, Wachenfeldt, Anna von, SWE-BRCA, Barkardottir, Rosa Bjork, Hamann, Ute, Rashid, Muhammad U, Lasa, Adriana, Caldés, Trinidad, Andrés, Raquel, Schmitt, Michael, Assmann, Volker, Stevens, Kristen, Offit, Kenneth, Curado, João, Tilgner, Hagen, Guigó, Roderic, Aiza, Gemma, Brunet, Joan, Castellsagué, Joan, and Martrat, Griselda

Subjects
HEBON, EMBRACE, SWE-BRCA, BCFR, GEMO Study Collaborators, kConFab, Breast, Cell Line, Tumor, Hela Cells, Microtubules, Epithelial Cells, Humans, Breast Neoplasms, Genetic Predisposition to Disease, Protein-Serine-Threonine Kinases, BRCA1 Protein, BRCA2 Protein, Receptors, Estrogen, Extracellular Matrix Proteins, Cell Polarity, Genotype, Heterozygote, Genes, BRCA1, Genes, BRCA2, Female, Genetic Variation, Aurora Kinase A, Aurora Kinases, Hyaluronan Receptors, HeLa Cells, Cell Line, Tumor, Receptors, Estrogen, Genes, BRCA1, BRCA2, Biological Sciences, Agricultural and Veterinary Sciences, Medical and Health Sciences, Developmental Biology
Abstract

Differentiated mammary epithelium shows apicobasal polarity, and loss of tissue organization is an early hallmark of breast carcinogenesis. In BRCA1 mutation carriers, accumulation of stem and progenitor cells in normal breast tissue and increased risk of developing tumors of basal-like type suggest that BRCA1 regulates stem/progenitor cell proliferation and differentiation. However, the function of BRCA1 in this process and its link to carcinogenesis remain unknown. Here we depict a molecular mechanism involving BRCA1 and RHAMM that regulates apicobasal polarity and, when perturbed, may increase risk of breast cancer. Starting from complementary genetic analyses across families and populations, we identified common genetic variation at the low-penetrance susceptibility HMMR locus (encoding for RHAMM) that modifies breast cancer risk among BRCA1, but probably not BRCA2, mutation carriers: n = 7,584, weighted hazard ratio ((w)HR) = 1.09 (95% CI 1.02-1.16), p(trend) = 0.017; and n = 3,965, (w)HR = 1.04 (95% CI 0.94-1.16), p(trend) = 0.43; respectively. Subsequently, studies of MCF10A apicobasal polarization revealed a central role for BRCA1 and RHAMM, together with AURKA and TPX2, in essential reorganization of microtubules. Mechanistically, reorganization is facilitated by BRCA1 and impaired by AURKA, which is regulated by negative feedback involving RHAMM and TPX2. Taken together, our data provide fundamental insight into apicobasal polarization through BRCA1 function, which may explain the expanded cell subsets and characteristic tumor type accompanying BRCA1 mutation, while also linking this process to sporadic breast cancer through perturbation of HMMR/RHAMM.

Published
2011

23. Supp Data from Tumor Evolution Inferred by Patterns of microRNA Expression through the Course of Disease, Therapy, and Recurrence in Breast Cancer

Author

Dadiani, Maya, primary, Bossel Ben-Moshe, Noa, primary, Paluch-Shimon, Shani, primary, Perry, Gili, primary, Balint, Nora, primary, Marin, Irina, primary, Pavlovski, Anya, primary, Morzaev, Dana, primary, Kahana-Edwin, Smadar, primary, Yosepovich, Ady, primary, Gal-Yam, Einav Nili, primary, Berger, Raanan, primary, Barshack, Iris, primary, Domany, Eytan, primary, and Kaufman, Bella, primary

Published
2023
Full Text
View/download PDF

24. Supplementary Table 1 from Efficacy of Chemotherapy in BRCA1/2 Mutation Carrier Ovarian Cancer in the Setting of PARP Inhibitor Resistance: A Multi-Institutional Study

Author

Ang, Joo Ern, primary, Gourley, Charlie, primary, Powell, C. Bethan, primary, High, Hilda, primary, Shapira-Frommer, Ronnie, primary, Castonguay, Vincent, primary, De Greve, Jacques, primary, Atkinson, Tina, primary, Yap, Timothy A., primary, Sandhu, Shahneen, primary, Banerjee, Susana, primary, Chen, Lee-May, primary, Friedlander, Michael L., primary, Kaufman, Bella, primary, Oza, Amit M., primary, Matulonis, Ursula, primary, Barber, Louise J., primary, Kozarewa, Iwanka, primary, Fenwick, Kerry, primary, Assiotis, Ioannis, primary, Campbell, James, primary, Chen, Lina, primary, de Bono, Johann S., primary, Gore, Martin E., primary, Lord, Christopher J., primary, Ashworth, Alan, primary, and Kaye, Stan B., primary

Published
2023
Full Text
View/download PDF

26. Data from Common Breast Cancer Susceptibility Alleles and the Risk of Breast Cancer for BRCA1 and BRCA2 Mutation Carriers: Implications for Risk Prediction

Author

Antoniou, Antonis C., primary, Beesley, Jonathan, primary, McGuffog, Lesley, primary, Sinilnikova, Olga M., primary, Healey, Sue, primary, Neuhausen, Susan L., primary, Ding, Yuan Chun, primary, Rebbeck, Timothy R., primary, Weitzel, Jeffrey N., primary, Lynch, Henry T., primary, Isaacs, Claudine, primary, Ganz, Patricia A., primary, Tomlinson, Gail, primary, Olopade, Olufunmilayo I., primary, Couch, Fergus J., primary, Wang, Xianshu, primary, Lindor, Noralane M., primary, Pankratz, Vernon S., primary, Radice, Paolo, primary, Manoukian, Siranoush, primary, Peissel, Bernard, primary, Zaffaroni, Daniela, primary, Barile, Monica, primary, Viel, Alessandra, primary, Allavena, Anna, primary, Dall'Olio, Valentina, primary, Peterlongo, Paolo, primary, Szabo, Csilla I., primary, Zikan, Michal, primary, Claes, Kathleen, primary, Poppe, Bruce, primary, Foretova, Lenka, primary, Mai, Phuong L., primary, Greene, Mark H., primary, Rennert, Gad, primary, Lejbkowicz, Flavio, primary, Glendon, Gord, primary, Ozcelik, Hilmi, primary, Andrulis, Irene L., primary, Thomassen, Mads, primary, Gerdes, Anne-Marie, primary, Sunde, Lone, primary, Cruger, Dorthe, primary, Birk Jensen, Uffe, primary, Caligo, Maria, primary, Friedman, Eitan, primary, Kaufman, Bella, primary, Laitman, Yael, primary, Milgrom, Roni, primary, Dubrovsky, Maya, primary, Cohen, Shimrit, primary, Borg, Ake, primary, Jernström, Helena, primary, Lindblom, Annika, primary, Rantala, Johanna, primary, Stenmark-Askmalm, Marie, primary, Melin, Beatrice, primary, Nathanson, Kate, primary, Domchek, Susan, primary, Jakubowska, Ania, primary, Lubinski, Jan, primary, Huzarski, Tomasz, primary, Osorio, Ana, primary, Lasa, Adriana, primary, Durán, Mercedes, primary, Tejada, Maria-Isabel, primary, Godino, Javier, primary, Benitez, Javier, primary, Hamann, Ute, primary, Kriege, Mieke, primary, Hoogerbrugge, Nicoline, primary, van der Luijt, Rob B., primary, Asperen, Christi J. van, primary, Devilee, Peter, primary, Meijers-Heijboer, E.J., primary, Blok, Marinus J., primary, Aalfs, Cora M., primary, Hogervorst, Frans, primary, Rookus, Matti, primary, Cook, Margaret, primary, Oliver, Clare, primary, Frost, Debra, primary, Conroy, Don, primary, Evans, D. Gareth, primary, Lalloo, Fiona, primary, Pichert, Gabriella, primary, Davidson, Rosemarie, primary, Cole, Trevor, primary, Cook, Jackie, primary, Paterson, Joan, primary, Hodgson, Shirley, primary, Morrison, Patrick J., primary, Porteous, Mary E., primary, Walker, Lisa, primary, Kennedy, M. John, primary, Dorkins, Huw, primary, Peock, Susan, primary, Godwin, Andrew K., primary, Stoppa-Lyonnet, Dominique, primary, de Pauw, Antoine, primary, Mazoyer, Sylvie, primary, Bonadona, Valérie, primary, Lasset, Christine, primary, Dreyfus, Hélène, primary, Leroux, Dominique, primary, Hardouin, Agnès, primary, Berthet, Pascaline, primary, Faivre, Laurence, primary, Loustalot, Catherine, primary, Noguchi, Tetsuro, primary, Sobol, Hagay, primary, Rouleau, Etienne, primary, Nogues, Catherine, primary, Frénay, Marc, primary, Vénat-Bouvet, Laurence, primary, Hopper, John L., primary, Daly, Mary B., primary, Terry, Mary B., primary, John, Esther M., primary, Buys, Saundra S., primary, Yassin, Yosuf, primary, Miron, Alexander, primary, Goldgar, David, primary, Singer, Christian F., primary, Dressler, Anne Catharina, primary, Gschwantler-Kaulich, Daphne, primary, Pfeiler, Georg, primary, Hansen, Thomas V.O., primary, Jønson, Lars, primary, Agnarsson, Bjarni A., primary, Kirchhoff, Tomas, primary, Offit, Kenneth, primary, Devlin, Vincent, primary, Dutra-Clarke, Ana, primary, Piedmonte, Marion, primary, Rodriguez, Gustavo C., primary, Wakeley, Katie, primary, Boggess, John F., primary, Basil, Jack, primary, Schwartz, Peter E., primary, Blank, Stephanie V., primary, Toland, Amanda Ewart, primary, Montagna, Marco, primary, Casella, Cinzia, primary, Imyanitov, Evgeny, primary, Tihomirova, Laima, primary, Blanco, Ignacio, primary, Lazaro, Conxi, primary, Ramus, Susan J., primary, Sucheston, Lara, primary, Karlan, Beth Y., primary, Gross, Jenny, primary, Schmutzler, Rita, primary, Wappenschmidt, Barbara, primary, Engel, Christoph, primary, Meindl, Alfons, primary, Lochmann, Magdalena, primary, Arnold, Norbert, primary, Heidemann, Simone, primary, Varon-Mateeva, Raymonda, primary, Niederacher, Dieter, primary, Sutter, Christian, primary, Deissler, Helmut, primary, Gadzicki, Dorothea, primary, Preisler-Adams, Sabine, primary, Kast, Karin, primary, Schönbuchner, Ines, primary, Caldes, Trinidad, primary, de la Hoya, Miguel, primary, Aittomäki, Kristiina, primary, Nevanlinna, Heli, primary, Simard, Jacques, primary, Spurdle, Amanda B., primary, Holland, Helene, primary, Chen, Xiaoqing, primary, Platte, Radka, primary, Chenevix-Trench, Georgia, primary, and Easton, Douglas F., primary

Published
2023
Full Text
View/download PDF

27. Supplementary Methods, Tables 1-3, Figure 1 from Common Breast Cancer Susceptibility Alleles and the Risk of Breast Cancer for BRCA1 and BRCA2 Mutation Carriers: Implications for Risk Prediction

Author

Antoniou, Antonis C., primary, Beesley, Jonathan, primary, McGuffog, Lesley, primary, Sinilnikova, Olga M., primary, Healey, Sue, primary, Neuhausen, Susan L., primary, Ding, Yuan Chun, primary, Rebbeck, Timothy R., primary, Weitzel, Jeffrey N., primary, Lynch, Henry T., primary, Isaacs, Claudine, primary, Ganz, Patricia A., primary, Tomlinson, Gail, primary, Olopade, Olufunmilayo I., primary, Couch, Fergus J., primary, Wang, Xianshu, primary, Lindor, Noralane M., primary, Pankratz, Vernon S., primary, Radice, Paolo, primary, Manoukian, Siranoush, primary, Peissel, Bernard, primary, Zaffaroni, Daniela, primary, Barile, Monica, primary, Viel, Alessandra, primary, Allavena, Anna, primary, Dall'Olio, Valentina, primary, Peterlongo, Paolo, primary, Szabo, Csilla I., primary, Zikan, Michal, primary, Claes, Kathleen, primary, Poppe, Bruce, primary, Foretova, Lenka, primary, Mai, Phuong L., primary, Greene, Mark H., primary, Rennert, Gad, primary, Lejbkowicz, Flavio, primary, Glendon, Gord, primary, Ozcelik, Hilmi, primary, Andrulis, Irene L., primary, Thomassen, Mads, primary, Gerdes, Anne-Marie, primary, Sunde, Lone, primary, Cruger, Dorthe, primary, Birk Jensen, Uffe, primary, Caligo, Maria, primary, Friedman, Eitan, primary, Kaufman, Bella, primary, Laitman, Yael, primary, Milgrom, Roni, primary, Dubrovsky, Maya, primary, Cohen, Shimrit, primary, Borg, Ake, primary, Jernström, Helena, primary, Lindblom, Annika, primary, Rantala, Johanna, primary, Stenmark-Askmalm, Marie, primary, Melin, Beatrice, primary, Nathanson, Kate, primary, Domchek, Susan, primary, Jakubowska, Ania, primary, Lubinski, Jan, primary, Huzarski, Tomasz, primary, Osorio, Ana, primary, Lasa, Adriana, primary, Durán, Mercedes, primary, Tejada, Maria-Isabel, primary, Godino, Javier, primary, Benitez, Javier, primary, Hamann, Ute, primary, Kriege, Mieke, primary, Hoogerbrugge, Nicoline, primary, van der Luijt, Rob B., primary, Asperen, Christi J. van, primary, Devilee, Peter, primary, Meijers-Heijboer, E.J., primary, Blok, Marinus J., primary, Aalfs, Cora M., primary, Hogervorst, Frans, primary, Rookus, Matti, primary, Cook, Margaret, primary, Oliver, Clare, primary, Frost, Debra, primary, Conroy, Don, primary, Evans, D. Gareth, primary, Lalloo, Fiona, primary, Pichert, Gabriella, primary, Davidson, Rosemarie, primary, Cole, Trevor, primary, Cook, Jackie, primary, Paterson, Joan, primary, Hodgson, Shirley, primary, Morrison, Patrick J., primary, Porteous, Mary E., primary, Walker, Lisa, primary, Kennedy, M. John, primary, Dorkins, Huw, primary, Peock, Susan, primary, Godwin, Andrew K., primary, Stoppa-Lyonnet, Dominique, primary, de Pauw, Antoine, primary, Mazoyer, Sylvie, primary, Bonadona, Valérie, primary, Lasset, Christine, primary, Dreyfus, Hélène, primary, Leroux, Dominique, primary, Hardouin, Agnès, primary, Berthet, Pascaline, primary, Faivre, Laurence, primary, Loustalot, Catherine, primary, Noguchi, Tetsuro, primary, Sobol, Hagay, primary, Rouleau, Etienne, primary, Nogues, Catherine, primary, Frénay, Marc, primary, Vénat-Bouvet, Laurence, primary, Hopper, John L., primary, Daly, Mary B., primary, Terry, Mary B., primary, John, Esther M., primary, Buys, Saundra S., primary, Yassin, Yosuf, primary, Miron, Alexander, primary, Goldgar, David, primary, Singer, Christian F., primary, Dressler, Anne Catharina, primary, Gschwantler-Kaulich, Daphne, primary, Pfeiler, Georg, primary, Hansen, Thomas V.O., primary, Jønson, Lars, primary, Agnarsson, Bjarni A., primary, Kirchhoff, Tomas, primary, Offit, Kenneth, primary, Devlin, Vincent, primary, Dutra-Clarke, Ana, primary, Piedmonte, Marion, primary, Rodriguez, Gustavo C., primary, Wakeley, Katie, primary, Boggess, John F., primary, Basil, Jack, primary, Schwartz, Peter E., primary, Blank, Stephanie V., primary, Toland, Amanda Ewart, primary, Montagna, Marco, primary, Casella, Cinzia, primary, Imyanitov, Evgeny, primary, Tihomirova, Laima, primary, Blanco, Ignacio, primary, Lazaro, Conxi, primary, Ramus, Susan J., primary, Sucheston, Lara, primary, Karlan, Beth Y., primary, Gross, Jenny, primary, Schmutzler, Rita, primary, Wappenschmidt, Barbara, primary, Engel, Christoph, primary, Meindl, Alfons, primary, Lochmann, Magdalena, primary, Arnold, Norbert, primary, Heidemann, Simone, primary, Varon-Mateeva, Raymonda, primary, Niederacher, Dieter, primary, Sutter, Christian, primary, Deissler, Helmut, primary, Gadzicki, Dorothea, primary, Preisler-Adams, Sabine, primary, Kast, Karin, primary, Schönbuchner, Ines, primary, Caldes, Trinidad, primary, de la Hoya, Miguel, primary, Aittomäki, Kristiina, primary, Nevanlinna, Heli, primary, Simard, Jacques, primary, Spurdle, Amanda B., primary, Holland, Helene, primary, Chen, Xiaoqing, primary, Platte, Radka, primary, Chenevix-Trench, Georgia, primary, and Easton, Douglas F., primary

Published
2023
Full Text
View/download PDF

28. Correction to: ESR1 mutations are frequent in newly diagnosed metastatic and loco-regional recurrence of endocrine-treated breast cancer and carry worse prognosis

Author

Zundelevich, Adi, Dadiani, Maya, Kahana-Edwin, Smadar, Itay, Amit, Sella, Tal, Gadot, Moran, Cesarkas, Karen, Farage-Barhom, Sarit, Saar, Efrat Glick, Eyal, Eran, Kol, Nitzan, Pavlovski, Anya, Balint-Lahat, Nora, Dick-Necula, Daniela, Barshack, Iris, Kaufman, Bella, and Gal-Yam, Einav Nili

Published
2020
Full Text
View/download PDF

31. Efficacy and safety of olaparib monotherapy in germline BRCA1/2 mutation carriers with advanced ovarian cancer and three or more lines of prior therapy

Author

Domchek, Susan M., Aghajanian, Carol, Shapira-Frommer, Ronnie, Schmutzler, Rita K., Audeh, M. William, Friedlander, Michael, Balmaña, Judith, Mitchell, Gillian, Fried, Georgeta, Stemmer, Salomon M., Hubert, Ayala, Rosengarten, Ora, Loman, Niklas, Robertson, Jane D., Mann, Helen, and Kaufman, Bella

Published
2016
Full Text
View/download PDF

32. Pregnancy after breast cancer: Are young patients willing to participate in clinical studies?

Author

Pagani, Olivia, Ruggeri, Monica, Manunta, Silvia, Saunders, Christobel, Peccatori, Fedro, Cardoso, Fatima, Kaufman, Bella, Paluch-Shimon, Shani, Gewefel, Hanan, Gallerani, Elisa, Abulkhair, OMalkahi, Pistilli, Barbara, Warner, Ellen, Saloustros, Emmanouil, Perey, Lucien, Zaman, Khalil, Rabaglio, Manuela, Gelber, Shari, Gelber, Richard D., Goldhirsch, Aron, Korde, Larissa, Azim, Hatem A., Jr., and Partridge, Ann H.

Published
2015
Full Text
View/download PDF

33. Divergence of mutational signatures in association with breast cancer subtype

Author

Perry, Gili, primary, Dadiani, Maya, additional, Kahana‐Edwin, Smadar, additional, Pavlovski, Anya, additional, Markus, Barak, additional, Hornung, Gil, additional, Balint‐Lahat, Nora, additional, Yosepovich, Ady, additional, Hout‐Siloni, Goni, additional, Jacob‐Hirsch, Jasmine, additional, Sklair‐Levy, Miri, additional, Friedman, Eitan, additional, Barshack, Iris, additional, Kaufman, Bella, additional, Gal‐Yam, Einav Nili, additional, and Paluch‐Shimon, Shani, additional

Published
2022
Full Text
View/download PDF

38. Screening for germline mutations in breast/ovarian cancer susceptibility genes in high-risk families in Israel

Author

Yablonski-Peretz, Tamar, Paluch-Shimon, Shani, Gutman, Lior Soussan, Kaplan, Yulia, Dvir, Addie, Barnes-Kedar, Inbal, Kadouri, Luna, Semenisty, Valeriya, Efrat, Noa, Neiman, Victoria, Glasser, Yafit, Michaelson-Cohen, Rachel, Katz, Lior, Kaufman, Bella, Golan, Talia, Reish, Orit, Hubert, Ayala, Safra, Tamar, Yaron, Yuval, and Friedman, Eitan

Published
2016
Full Text
View/download PDF

39. Clinical outcomes in patients with node-negative breast cancer treated based on the recurrence score results: evidence from a large prospectively designed registry

Author

Stemmer, Salomon M., Steiner, Mariana, Rizel, Shulamith, Soussan-Gutman, Lior, Ben-Baruch, Noa, Bareket-Samish, Avital, Geffen, David B., Nisenbaum, Bella, Isaacs, Kevin, Fried, Georgeta, Rosengarten, Ora, Uziely, Beatrice, Svedman, Christer, McCullough, Debbie, Maddala, Tara, Klang, Shmuel H., Zidan, Jamal, Ryvo, Larisa, Kaufman, Bella, Evron, Ella, Karminsky, Natalya, Goldberg, Hadassah, Shak, Steven, and Liebermann, Nicky

Published
2017
Full Text
View/download PDF

40. Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer: interim efficacy results of the randomised, open-label, non-inferiority, phase 3 TURANDOT trial

Author

Lang, Istvan, Brodowicz, Thomas, Ryvo, Larisa, Kahan, Zsuzsanna, Greil, Richard, Beslija, Semir, Stemmer, Salomon M, Kaufman, Bella, Zvirbule, Zanete, Steger, Günther G, Melichar, Bohuslav, Pienkowski, Tadeusz, Sirbu, Daniela, Messinger, Diethelm, and Zielinski, Christoph

Published
2013
Full Text
View/download PDF

45. Niraparib for Advanced Breast Cancer with Germline BRCA1 and BRCA2 Mutations: the EORTC 1307-BCG/BIG5–13/TESARO PR-30–50–10-C BRAVO Study

Author

Turner, Nicholas C., primary, Balmaña, Judith, additional, Poncet, Coralie, additional, Goulioti, Theodora, additional, Tryfonidis, Konstantinos, additional, Honkoop, Aafke H., additional, Zoppoli, Gabriele, additional, Razis, Evangelia, additional, Johannsson, Oskar T., additional, Colleoni, Marco, additional, Tutt, Andrew N., additional, Audeh, William, additional, Ignatiadis, Michail, additional, Mailliez, Audrey, additional, Trédan, Olivier, additional, Musolino, Antonino, additional, Vuylsteke, Peter, additional, Juan-Fita, Maria Jose, additional, Macpherson, Iain R.J., additional, Kaufman, Bella, additional, Manso, Luis, additional, Goldstein, Lori J., additional, Ellard, Susan L., additional, Láng, István, additional, Jen, Kai Yu, additional, Adam, Virginie, additional, Litière, Saskia, additional, Erban, John, additional, and Cameron, David A., additional

Published
2021
Full Text
View/download PDF

46. OlympiA: A phase III, multicenter, randomized, placebo-controlled trial of adjuvant olaparib after (neo)adjuvant chemotherapy in patients with germline BRCA1/2 mutations and high-risk HER2-negative early breast cancer.

Author

Tutt, Andrew, primary, Garber, Judy Ellen, additional, Kaufman, Bella, additional, Viale, Giuseppe, additional, Fumagalli, Debora, additional, Rastogi, Priya, additional, Gelber, Richard D., additional, de Azambuja, Evandro, additional, Fielding, Anitra, additional, Balmana Gelpi, Judith, additional, Gelmon, Karen A., additional, Baker, Nigel, additional, Arahmani, Amal, additional, Senkus-Konefka, Elzbieta, additional, Mc Fadden, Eleanor, additional, Karantza, Vassiliki, additional, Lakhani, Sunil R., additional, Yothers, Greg, additional, Campbell, Christine, additional, and Geyer, Charles E., additional

Published
2021
Full Text
View/download PDF

47. Relevance of Platinum-free Interval and BRCA Reversion Mutations for Veliparib Monotherapy after Progression on Carboplatin/Paclitaxel for gBRCA Advanced Breast Cancer (BROCADE3 Crossover)

Author

Puhalla, Shannon L., primary, Diéras, Véronique, additional, Arun, Banu K., additional, Kaufman, Bella, additional, Wildiers, Hans, additional, Han, Hyo S., additional, Ayoub, Jean-Pierre, additional, Stearns, Vered, additional, Yuan, Yuan, additional, Helsten, Teresa, additional, Riley-Gillis, Bridget, additional, Murphy, Erin, additional, Kundu, Madan G., additional, Wu, Meijing, additional, Maag, David, additional, Ratajczak, Christine K., additional, Ramathal, Cyril Y., additional, and Friedlander, Michael, additional

Published
2021
Full Text
View/download PDF

49. Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer

Author

Tutt, Andrew N J, Garber, Judy E, Kaufman, Bella, Viale, Giuseppe, Fumagalli, Debora, Rastogi, Priya, Gelber, Richard D, de Azambuja, Evandro, Fielding, Anitra, Balmaña, Judith, Domchek, Susan M, Gelmon, Karen A, Hollingsworth, Simon J, Korde, Larissa A, Linderholm, Barbro, Bandos, Hanna, Senkus, Elżbieta, Suga, Jennifer M, Shao, Zhimin, Pippas, Andrew W, Nowecki, Zbigniew, Huzarski, Tomasz, Ganz, Patricia A, Lucas, Peter C, Baker, Nigel, Loibl, Sibylle, McConnell, Robin, Piccart, Martine, Schmutzler, Rita, Steger, Guenther G, Costantino, Joseph P, Arahmani, Amal, Wolmark, Norman, McFadden, Eleanor, Karantza, Vassiliki, Lakhani, Sunil R, Yothers, Greg, Campbell, Christine, and Geyer, Charles E

Subjects
610 Medicine & health
Abstract

BACKGROUND Poly(adenosine diphosphate-ribose) polymerase inhibitors target cancers with defects in homologous recombination repair by synthetic lethality. New therapies are needed to reduce recurrence in patients with BRCA1 or BRCA2 germline mutation-associated early breast cancer. METHODS We conducted a phase 3, double-blind, randomized trial involving patients with human epidermal growth factor receptor 2 (HER2)-negative early breast cancer with BRCA1 or BRCA2 germline pathogenic or likely pathogenic variants and high-risk clinicopathological factors who had received local treatment and neoadjuvant or adjuvant chemotherapy. Patients were randomly assigned (in a 1:1 ratio) to 1 year of oral olaparib or placebo. The primary end point was invasive disease-free survival. RESULTS A total of 1836 patients underwent randomization. At a prespecified event-driven interim analysis with a median follow-up of 2.5 years, the 3-year invasive disease-free survival was 85.9% in the olaparib group and 77.1% in the placebo group (difference, 8.8 percentage points; 95% confidence interval [CI], 4.5 to 13.0; hazard ratio for invasive disease or death, 0.58; 99.5% CI, 0.41 to 0.82; P

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results